Boston-based biotechnology company Elektrofi revealed on Wednesday that it has appointed Paul Herbert to the role of senior vice president of Pharmaceutical Development.
The company said Herbert is a highly experienced senior executive with a proven track record of about 30 years in the pharmaceutical industry.
Herbert is a an expert in product development and manufacturing for particle-based products and has led the development of twelve processes to NDA submission.
Before joining Elektrofi, Herbert served as vice president of Process Development & Engineering at Alkermes, where he led teams of up to 100 individuals in all aspects of drug product operations, including sterile process design, regulatory documentation, CDMO/CMO management, and clinical manufacturing.
Elektrofi is focused on improving administration for a range of medicines, such as monoclonal antibodies, therapeutic proteins and other large molecule drugs. The company's breakthrough formulation platform is designed to enable stabilized, highly concentrated formulations for subcutaneous administration.
EDX Medical to provide molecular profiling services to Astron Health
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
Sensei Biotherapeutics changes name to Faeth Therapeutics
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Atrium Therapeutics announces inducement grants to seven new employees